Approval Alert | Liso-Cel for Relapsed/Refractory LBCL in Second Line

Catherine S. Diefenbach, MD, spoke about refining understanding of CAR T-cell therapies after the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma.

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who do not have chemotherapy-sensitive disease.

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma following 1 prior therapy.

Based on results from the phase 3 TRANSFORM trial, the FDA has approved lisocabtagene maraleucel for the second-line treatment of relapsed/refractory large B-cell lymphoma.